Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASDAQ 4,034.16 11.47 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,091.52 -40.05 -1.28%
FTSE 100 6,541.61 -42.15 -0.64%
DAX 9,173.71 -165.46 -1.77%
Ticker Volume Price Price Delta
NIKKEI 14,355.01 358.20 2.56%
TOPIX 1,161.12 25.03 2.20%
HANG SENG 22,813.92 142.66 0.63%

Sucampo Pharmaceuticals to Present at Investment Conferences



  Sucampo Pharmaceuticals to Present at Investment Conferences

BIO CEO & Investor Conference 2013

Business Wire

BETHESDA, Md. -- February 6, 2013

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that it will
webcast its corporate presentation at two upcoming investment conferences in
New York City:

  * Mr. Cary J. Claiborne, CFO of Sucampo, will present at the 15th Annual BIO
    CEO & Investor Conference on Tuesday, February 12 at 1:00 pm Eastern.
  * Mr. Claiborne will also host a fireside chat at the Leerink Swann Global
    Healthcare Conference 2013 on Thursday, February 14 at 1:30 pm Eastern.

The presentations will be webcast live and may be accessed from the Event
Calendar page of Sucampo’s website at
http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar.
Presentation slides will be available via the webcast links. A replay of both
webcasts will also be available on the Company’s website for several days
after the live events. To ensure a timely connection, it is recommended that
users register at least 15 minutes prior to the scheduled webcast.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on
innovative research, discovery, development and commercialization of
proprietary drugs based on prostones. The therapeutic potential of prostones
was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman,
Chief Executive Officer, Chief Scientific Officer, and co-founder. Prostones,
naturally occurring fatty acid metabolites that have emerged as promising
compounds with unique physiological activities, can be targeted for the
treatment of unmet or underserved medical needs. For more information, please
visit www.sucampo.com.

Sucampo Forward-Looking Statement

This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, future financial and
operating results, and other statements that are not historical facts. The
following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the impact of
pharmaceutical industry regulation and health care legislation; Sucampo's
ability to accurately predict future market conditions; dependence on the
effectiveness of Sucampo's patents and other protections for innovative
products; the risk of new and changing regulation and health policies in the
US and internationally and the exposure to litigation and/or regulatory
actions.

No forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Sucampo undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events, or otherwise. Forward-looking statements in this presentation
should be evaluated together with the many uncertainties that affect Sucampo's
business, particularly those mentioned in the risk factors and cautionary
statements in Sucampo's most recent Form 8-K and 10-K, which the Company
incorporates by reference.

Contact:

Sucampo Pharmaceuticals, Inc.
Silvia Taylor, 1-240-223-3718
staylor@sucampo.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement